StockData
CytoMed Therapeutics Ltd logo

CytoMed Therapeutics Ltd (GDTC) stock

GDTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026Score 4/30
$0.78+0.01 (+1.18%)

Close on Nov 17, 2026Market cap $9.26MP/E –Yield –

CytoMed Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was 2.22M SGD, up 16.1% from the year before. The highest annual figure on record is 2.22M SGD in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 20252.22M SGD+16.1%
FY2024Dec 31, 20241.91M SGD+20.1%
FY2023Dec 31, 20231.59M SGD+4.4%
FY2022Dec 31, 20221.52M SGD+39.6%
FY2021Dec 31, 20211.09M SGD+5.1%
FY2020Dec 31, 20201.04M SGD–

More CytoMed Therapeutics figures

See a number that looks wrong?